Journal article
Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice
Abstract
Sterol regulatory element binding protein (SREBP) is an important potential mediator of kidney fibrosis and is known to be upregulated in diabetic nephropathy. We evaluated the effectiveness of SREBP inhibition as treatment of diabetic nephropathy. Type 1 diabetes was induced in uninephrectomized male CD1 mice with streptozotocin. The mice were treated with the SREBP inhibitor fatostatin for 12 weeks. At the endpoint, kidney function and …
Authors
Van Krieken R; Marway M; Parthasarathy P; Mehta N; Ingram AJ; Gao B; Krepinsky JC
Journal
Endocrinology, Vol. 159, No. 3, pp. 1479–1495
Publisher
The Endocrine Society
Publication Date
March 1, 2018
DOI
10.1210/en.2018-00093
ISSN
0013-7227